Please login to the form below

Not currently logged in
Email:
Password:

Astellas to close US urology research facility

Work at Urogenix, North Carolina site will end by the end of the year

Astellas is to close its Urogenix urology drug discovery facility in North Carolina, with the loss of 13 jobs, by the end of the year.

The Japanese pharma company acquired the facility from Dynogen Pharmaceuticals in 2006 and gave it a particular focus on researching new treatments for lower urinary tract disorder. 

Astellas will transfer its urology research activities to Astellas' Tsukuba Research Center in Japan and said the decision to shut down the unit would allow it to optimise its research and development resource allocation.

6th August 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
First Line Research

We specialise in online and behavioural research methods. Established in January 2004, we have over 40 years collective research experience...

Latest intelligence

How do you solve a problem like non-adherence? Part 1
Recent research from the World Health Organisation and the Mayo Clinic on the impact of (and influences on) a patient’s ability to adhere to their treatment regime has shown that...
How to design patient services with social media within the ABPI code guidelines
In this blog, Senior Consultant Craig Moore, from the Blue Latitude Strategy team, discusses the application of the ABPI Code, including incorporating social media into digital patient services....
Infographic: PsO market snapshot
...

Infographics